Resveratrol for Cancer Risk Reduction

Research suggests that resveratrol may play a role in cancer risk reduction through several biological mechanisms, including suppression of the pro-inflammatory enzyme Cox-2, inhibition of tumor cell proliferation, and promotion of cancer cell death, with animal and cell culture studies providing the bulk of supporting evidence. The available literature consists primarily of review articles and preclinical studies rather than human clinical trials, and one review explicitly cautions that laboratory concentrations of resveratrol used in preclinical research are often far higher than what can realistically be achieved in the human body, raising questions about how well these findings translate to real-world use. A study on pine knot extract, which contains resveratrol among other compounds, showed measurable anti-tumor effects in mice and confirmed that key compounds reached the bloodstream at biologically relevant levels, though the mixed-compound nature of the extract makes it difficult to attribute effects to resveratrol alone. Overall, the evidence is promising but largely preliminary, and researchers have called for better-designed clinical studies with validated biomarkers to determine whether these laboratory findings can be meaningfully replicated in humans.